A reaffirmed bullish outlook from a prominent analyst and fresh institutional investment have placed ImmunityBio in the spotlight this week. This dual vote of confidence has improved market sentiment, raising questions about its potential to provide lasting support for the biotech firm’s stock.
Commercial Momentum and Financial Position
The underlying driver for the recent interest appears to be robust commercial progress. For the third quarter of 2025, ImmunityBio reported product revenue for ANKTIVA of $31.8 million. This figure represents a staggering 434% increase compared to the same period last year. Year-to-date sales have accumulated to approximately $75 million, with units sold soaring by 467%. These metrics suggest the company is successfully translating regulatory approvals into tangible revenue.
Despite this explosive growth, ImmunityBio remains in an investment phase. Its quarterly net loss narrowed to $67.3 million from $85.7 million in the prior-year quarter. Executive Chairman Dr. Patrick Soon-Shiong has publicly emphasized the strategic importance of technology-driven approaches in healthcare, such as inference-based chips, highlighting the company’s forward-looking direction.
The stock closed its latest session at €1.89. Since the start of the year, it has declined by roughly 24%, with its 52-week high standing at €3.75.
Analyst Conviction and Institutional Activity
Adding significant fuel to the positive sentiment, D. Boral Capital recently reiterated its “Buy” rating on ImmunityBio. The firm assigned a price target of $24 per share, which, according to their analysis, implies a potential upside of approximately 950% from recent trading levels. Such a substantial target underscores the analyst’s strong conviction in the long-term commercial prospects of the company’s pipeline.
Should investors sell immediately? Or is it worth buying ImmunityBio?
This optimistic view is being mirrored in the actions of major investors. Recent 13F regulatory filings reveal that several hedge funds and institutional managers have either established new positions or significantly increased their existing stakes:
* Heights Capital Management Inc.: Initiated a new position valued at around $16.15 million.
* Woodline Partners LP: Boosted its holdings by 53.7%, now owning over 5.2 million shares.
* Alpine Global Management LLC and Swiss Life Asset Management: Both commenced new positions in the company.
While these movements help explain the improved short-term mood, they do not automatically negate the company’s inherent execution risks.
Outlook and Key Factors to Watch
The vast gap between the ambitious analyst target and the current market valuation perfectly illustrates the classic risk/reward profile of biotechnology stocks: substantial potential upside paired with significant operational risk. The commercial performance for Q4 2025 will be critical; if the exponential growth rates are maintained, the likelihood of a meaningful market re-rating increases.
From a technical perspective, the shares are currently testing a resistance zone just above $2.30–$2.40. A sustained breakout above this level could pave the way for a move toward $3.00 in the near term. Conversely, a failure to hold support above $2.00 would notably weaken the short-term bullish case. Upcoming catalysts include updated guidance on the pipeline expansion for ANKTIVA and the release of full-year financial forecasts.
Ad
ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from January 28 delivers the answer:
The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 28.
ImmunityBio: Buy or sell? Read more here...
